{"id":755412,"date":"2023-05-04T19:30:35","date_gmt":"2023-05-04T23:30:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/"},"modified":"2023-05-04T19:30:35","modified_gmt":"2023-05-04T23:30:35","slug":"horizon-therapeutics-plc-horizon-rule-2-12-announcement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/","title":{"rendered":"Horizon Therapeutics plc (\u201cHorizon\u201d) &#8211; Rule 2.12 Announcement"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\">\n\u00a0<b>Horizon Therapeutics plc (\u201cHorizon\u201d) &#8211; <\/b><b>Rule 2.12 Announcement<\/b><\/p>\n<p>DUBLIN&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nIn accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the \u201c<b>Irish Takeover Rules<\/b>\u201d), Horizon confirms that, as of the close of business on March 31, 2023, Horizon\u2019s issued ordinary share capital is comprised of 228,576,339 ordinary shares, nominal value $0.0001 per share (the \u201c<b>Ordinary<\/b><b>Shares<\/b>\u201d) and 40,000 deferred ordinary shares of \u20ac1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol \u201cHZNP\u201d. The International Securities Identification Number for these securities is IE00BQPVQZ61.<\/p>\n<p>\nThe Company confirms that as of March 31, 2023, there were outstanding options to purchase up to 4,672,774 Ordinary Shares and outstanding restricted stock units and performance stock units conferring on their holders vested or unvested rights to convert into, or receive, up to an aggregate of 1,810,200 Ordinary Shares and incremental restricted stock units to be issued of 4,261,147 Ordinary Shares.<\/p>\n<p><b>About Horizon<\/b><\/p>\n<p>\nHorizon Therapeutics plc is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.horizontherapeutics.com&amp;esheet=53394267&amp;newsitemid=20230504006075&amp;lan=en-US&amp;anchor=www.horizontherapeutics.com&amp;index=1&amp;md5=176e93c769068aa6c3d7613d1f811aae\">www.horizontherapeutics.com<\/a>.<\/p>\n<p><b>Statement Required by the Irish Takeover Rules<\/b><\/p>\n<p>\nThe directors of Horizon accept responsibility for the information contained in this document. To the best of the knowledge and belief of the directors of Horizon (who have taken all reasonable care to ensure such is the case), the information contained in this document for which they respectively accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.<\/p>\n<p><b>Dealing Disclosure Requirements<\/b><\/p>\n<p>\nUnder the provisions of Rule 8.3(b) of the Irish Takeover Rules, if any person is, or becomes, \u2018interested\u2019 (directly or indirectly) in 1% or more of any class of \u2018relevant securities\u2019 of Horizon (including by means of an option in respect of, or a derivative referenced to, any such \u2018relevant securities\u2019), that person must publicly disclose all \u2018dealings\u2019 in any \u2018relevant securities\u2019 of Horizon during the \u2018offer period,\u2019 by not later than 3:30 p.m. (E.T.) on the \u2018business day\u2019 following the date of the relevant transaction.<\/p>\n<p>\nIf two or more persons co-operate on the basis of any agreement either express or tacit, either oral or written, to acquire an \u2018interest\u2019 in \u2018relevant securities\u2019 of Horizon, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules.<\/p>\n<p>\nA disclosure table, giving details of the companies in whose \u2018relevant securities\u2019 and \u2018dealings\u2019 should be disclosed can be found on the Irish Takeover Panel\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.irishtakeoverpanel.ie&amp;esheet=53394267&amp;newsitemid=20230504006075&amp;lan=en-US&amp;anchor=www.irishtakeoverpanel.ie&amp;index=2&amp;md5=fe96b01e74b74248fb0e99f7d0c606bf\">www.irishtakeoverpanel.ie<\/a>.<\/p>\n<p>\n\u2018Interests\u2019 in securities arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an \u2018interest\u2019 by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.<\/p>\n<p>\nTerms in quotation marks are defined in the Irish Takeover Rules, which can be found on the Irish Takeover Panel\u2019s website. If you are in any doubt as to whether or not you are required to disclose a \u2018dealing\u2019 under Rule 8, please consult the Irish Takeover Panel\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.irishtakeoverpanel.ie&amp;esheet=53394267&amp;newsitemid=20230504006075&amp;lan=en-US&amp;anchor=www.irishtakeoverpanel.ie&amp;index=3&amp;md5=65f474e7677d864465f8925428d9830a\">www.irishtakeoverpanel.ie<\/a> or contact the Irish Takeover Panel at telephone number +353 1 678 9020.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504006075r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230504006075\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230504006075\/en\/<\/a><\/span><\/p>\n<p><span class=\"bwuline\">Horizon Investor Relations<br \/>\n<\/span><br \/><a rel=\"nofollow\" href=\"mailto:investor-relations@horizontherapeutics.com\">investor-relations@horizontherapeutics.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> New York Europe Ireland United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology General Health Other Health Health Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230504006075\/en\/1460023\/3\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0Horizon Therapeutics plc (\u201cHorizon\u201d) &#8211; Rule 2.12 Announcement DUBLIN&#8211;(BUSINESS WIRE)&#8211; In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the \u201cIrish Takeover Rules\u201d), Horizon confirms that, as of the close of business on March 31, 2023, Horizon\u2019s issued ordinary share capital is comprised of 228,576,339 ordinary shares, nominal value $0.0001 per share (the \u201cOrdinaryShares\u201d) and 40,000 deferred ordinary shares of \u20ac1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol \u201cHZNP\u201d. The International Securities Identification Number for these securities is IE00BQPVQZ61. The Company confirms that as of March 31, 2023, there were outstanding &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Horizon Therapeutics plc (\u201cHorizon\u201d) &#8211; Rule 2.12 Announcement&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-755412","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Horizon Therapeutics plc (\u201cHorizon\u201d) - Rule 2.12 Announcement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Horizon Therapeutics plc (\u201cHorizon\u201d) - Rule 2.12 Announcement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u00a0Horizon Therapeutics plc (\u201cHorizon\u201d) &#8211; Rule 2.12 Announcement DUBLIN&#8211;(BUSINESS WIRE)&#8211; In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the \u201cIrish Takeover Rules\u201d), Horizon confirms that, as of the close of business on March 31, 2023, Horizon\u2019s issued ordinary share capital is comprised of 228,576,339 ordinary shares, nominal value $0.0001 per share (the \u201cOrdinaryShares\u201d) and 40,000 deferred ordinary shares of \u20ac1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol \u201cHZNP\u201d. The International Securities Identification Number for these securities is IE00BQPVQZ61. The Company confirms that as of March 31, 2023, there were outstanding &hellip; Continue reading &quot;Horizon Therapeutics plc (\u201cHorizon\u201d) &#8211; Rule 2.12 Announcement&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T23:30:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504006075r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Horizon Therapeutics plc (\u201cHorizon\u201d) &#8211; Rule 2.12 Announcement\",\"datePublished\":\"2023-05-04T23:30:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\\\/\"},\"wordCount\":645,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230504006075r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\\\/\",\"name\":\"Horizon Therapeutics plc (\u201cHorizon\u201d) - Rule 2.12 Announcement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230504006075r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-05-04T23:30:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230504006075r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230504006075r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Horizon Therapeutics plc (\u201cHorizon\u201d) &#8211; Rule 2.12 Announcement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Horizon Therapeutics plc (\u201cHorizon\u201d) - Rule 2.12 Announcement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/","og_locale":"en_US","og_type":"article","og_title":"Horizon Therapeutics plc (\u201cHorizon\u201d) - Rule 2.12 Announcement - Market Newsdesk","og_description":"\u00a0Horizon Therapeutics plc (\u201cHorizon\u201d) &#8211; Rule 2.12 Announcement DUBLIN&#8211;(BUSINESS WIRE)&#8211; In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the \u201cIrish Takeover Rules\u201d), Horizon confirms that, as of the close of business on March 31, 2023, Horizon\u2019s issued ordinary share capital is comprised of 228,576,339 ordinary shares, nominal value $0.0001 per share (the \u201cOrdinaryShares\u201d) and 40,000 deferred ordinary shares of \u20ac1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol \u201cHZNP\u201d. The International Securities Identification Number for these securities is IE00BQPVQZ61. The Company confirms that as of March 31, 2023, there were outstanding &hellip; Continue reading \"Horizon Therapeutics plc (\u201cHorizon\u201d) &#8211; Rule 2.12 Announcement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-04T23:30:35+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504006075r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Horizon Therapeutics plc (\u201cHorizon\u201d) &#8211; Rule 2.12 Announcement","datePublished":"2023-05-04T23:30:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/"},"wordCount":645,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504006075r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/","name":"Horizon Therapeutics plc (\u201cHorizon\u201d) - Rule 2.12 Announcement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504006075r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-05-04T23:30:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504006075r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504006075r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-horizon-rule-2-12-announcement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Horizon Therapeutics plc (\u201cHorizon\u201d) &#8211; Rule 2.12 Announcement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=755412"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755412\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=755412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=755412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=755412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}